NGS based molecular assays development and validation for precision oncology (ANID/FONDEF, Roche, Pfizer, illumina, UDD & Fundación CancerVida)
Developing liquid biopsy assays to detect oncogenic markers in blood plasma for upfront cancer diagnosis, prognosis, and treatment.
Molecular characterization of pan-cancer tumors in South American patients to uncover novel driver mutations in actionable genes (ANID/Anillo/FONDECYT, Roche & GOCCHI).
Genetic variation of the Chilean population and its impact on the diagnosis of somatic mutations for precision oncology.
Discovery and validation of novel driver mutations in actionable genes.
Discovering and understanding resistance mechanisms to cancer treatment (ANID/FONDECYT/Anillo).
Adenosine Deaminase RNA Specific (ADAR) regulates the breast cancer drug response.
Novel mechanism and biomarkers predicting therapy response in advanced breast cancer.